Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + leuprolide + testosterone
- Development stage
- Discontinued
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Peptides, Small Molecules
- Administration
- Intravenous, Topical, Subcutaneous
01
Overview
This investigational combination therapy, evaluated by Memorial Sloan Kettering Cancer Center (MSKCC), consists of the taxane chemotherapy docetaxel administered alongside a "rapid hormonal cycling" regimen of leuprolide and topical testosterone. Docetaxel acts as a microtubule stabilizer, binding to the interior surface of microtubules to prevent mitotic spindle assembly, thereby inducing cell cycle arrest and apoptosis. Leuprolide, a GnRH agonist, is used to deplete endogenous testosterone levels, while topical testosterone gel is used for periodic repletion. This approach aims to exploit the sensitivity of prostate cancer cells to fluctuating androgen levels to enhance the apoptotic effect of chemotherapy. The regimen was specifically studied in patients with progressive non-castrate prostate adenocarcinoma.
- Brand names
- TaxotereLupronAndroGel
- Other names
- Docetaxel With Rapid Hormonal CyclingDocetaxel with rapid androgen cycling
02
Targets
TUBB (Tubulin (alpha and beta subunits))GnRHR (Gonadotropin-releasing hormone receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on docetaxel + leuprolide + testosterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + leuprolide + testosterone.